XRpro Sciences
Boston, US · Delaware corporation
Founders & leadership
RC
Richard CunninghamExecutive
MK
Mark KorbExecutive
BW
Benjamin WarnerNamed on SEC filing
Board
CK
Clive KabatznikBoard director
MT
Michael TaglichBoard director
ER
Edward RoffmanBoard director
TT
Timothy TysonBoard director
VP
Vincent PalmieriBoard director
Reported raises · per SEC filings
Form D private placements$23.3M disclosed across 7 rounds · 2014–2018
▶$7.3MraisedSep 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$7.3MraisedSep 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Vincent PalmieriDirector
- Timothy TysonDirector
- Douglas KrafteExecutive Officer
- Mark KorbExecutive Officer
- Edward RoffmanDirector
- Richard CunninghamExecutive Officer
- Clive KabatznikDirector
- Michael TaglichDirector
- Offering amount
- $7.3M
- Amount sold
- $7.3M
- Finders' fees
- $307.5K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedAug 2018 · 4 investors · PharmaceuticalsRule 506(b)
▶$500KraisedAug 2018 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Timothy TysonDirector
- Mark KorbExecutive Officer
- Douglas KrafteExecutive Officer
- Clive KabatznikDirector
- Vincent PalmieriDirector
- Richard CunninghamExecutive Officer
- Michael TaglichDirector
- Edward RoffmanDirector
- Offering amount
- $1.5M
- Amount sold
- $500K
- Minimum investment
- $10K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedApr 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$2MraisedApr 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Douglas KrafteDirector
- Richard CunninghamExecutive Officer
- Mark KorbExecutive Officer
- Timothy TysonDirector
- Vincent PalmieriDirector
- Clive KabatznikDirector
- Edward RoffmanDirector
- Michael TaglichDirector
- Offering amount
- $4M
- Amount sold
- $2M
- Minimum investment
- $100K
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedMay 2017 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedMay 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas KrafteExecutive Officer
- Michael TaglichDirector
- Clive KabatznikDirector
- Edward RoffmanDirector
- Vincent PalmieriDirector
- Mark KorbExecutive Officer
- Benjamin WarnerDirector
- Richard CunninghamExecutive Officer
- Timothy TysonDirector
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedApr 2017 · 3 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedApr 2017 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Timothy TysonDirector
- Mark KorbExecutive Officer
- Benjamin WarnerDirector
- Douglas KrafteExecutive Officer
- Richard CunninghamExecutive Officer
- Michael TaglichDirector
- Vincent PalmieriDirector
- Clive KabatznikDirector
- Edward RoffmanDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Minimum investment
- $500K
- Sales commissions
- $60K
- Placement agents
- "TAGLICH BROTHERS, INC. (""TAGLICH"")"
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedJul 2016 · 12 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedJul 2016 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Clive KabatznikDirector
- Mark KorbExecutive Officer
- Timothy TysonDirector
- Richard CunninghamExecutive Officer
- Vincent PalmieriDirector
- Benjamin WarnerDirector
- Michael TaglichDirector
- Edward RoffmanDirector
- Douglas KrafteExecutive Officer
- Offering amount
- $1.1M
- Amount sold
- $1.1M
- Minimum investment
- $10K
- Sales commissions
- $68.7K
- Placement agents
- Taglich Brothers, Inc.
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.9MraisedJan 2015 · 162 investors · PharmaceuticalsRule 506(b)
▶$8.9MraisedJan 2015 · 162 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Clive KabatznikDirector
- Michael TaglichDirector
- Richard CunninghamExecutive Officer
- Edward RoffmanDirector
- Mark KorbExecutive Officer
- Timothy TysonDirector
- Benjamin WarnerExecutive Officer, Director
- Vincent PalmieriDirector
- Offering amount
- $8.9M
- Amount sold
- $8.9M
- Minimum investment
- $10K
- Sales commissions
- $708.4K
- Placement agents
- Taglich Brothers, Inc.
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has XRpro Sciences raised?
- XRpro Sciences has disclosed $23.3M raised across 7 rounds.
- Where is XRpro Sciences headquartered?
- XRpro Sciences is headquartered in Boston, US.